Novartis collaboration on HLA class II prediction
In a collaboration with Novartis, we (SciCross) has developed a method for improved HLA class II binding prediction based on MAPPs data. The results till be presented at the Immunogenicity and Bioassay Summit (https://www.immunogenicitysummit.com/), which in 2020 will be hosted as a virtual conference. And yes, the performance accuracy of the methods is great!